Mersana Therapeutics Inc
NASDAQ:MRSN
| Market Cap (Intraday) | 250.56M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $1.95 |
| 50-Day MA | $1.69 |
| 200-Day MA | $2.81 |
Mersana Therapeutics Inc Stock, NASDAQ:MRSN
840 Memorial Drive, Cambridge, Massachusetts 02139
United States of America
Phone: +1.617.498.0020
Number of Employees: 123
Description
Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of antibody-drug conjugates that offer clinical benefit for cancer patients. Its product candidates are Upifitamab Rilsodotin (UpRi), XMT-1536, and XMT-1592. The company was founded by Mikhail Papisov in 2001 and is headquartered in Cambridge, MA.